Three to Six Months: Long-Term Results and Optimization The 3 to 6-month window typically brings the most dramatic visible changes, with total weight loss ranging from 8% to 15% of starting weight
Currently, oral PYY analogs have entered preclinical research stages, with preliminary results showing they can effectively reduce food intake in mice and improve glucose tolerance (156, 162)
These GLP-1s can also safely be used off label for weight loss
Highlights of prescribing information
Retatrutide is a next-generation peptide designed to act on three key metabolic hormone pathways simultaneously: GLP-1 (Glucagon-Like Peptide-1) GIP (Glucose-Dependent Insulinotropic Polypeptide) Glucagon receptors Because of this triple-agonist action, retatrutide works systemically influencing the brain, liver, pancreas, fat tissue, and inflammatory pathways at the same time.This multi-targeted design is what separates retatrutide from earlier peptides and medications
Among the 81,617 participants who already had a substance use disorder, the researchers tracked serious health outcomes